AVXL - Anavex Corp Forward P/E Multiple

Graphic logo of anavex.com (AVXL)

Strict FDA oversight and small-molecule patent protection create significant barriers to entry for competitors. The forward P/E ratio of Anavex Life Sciences confirms these market expectations, and the metric currently stands at 0.00. Diversification of CNS research mitigates scientific risks, while the success of its unique platform in clinical phases brings Anavex Life Sciences closer to leadership in Alzheimer's disease therapy.

anavex.com - AVXL Future Price to Earnings (period 07/04/2022 - 11/16/2026)

Anavex Life Sciences Corp. (AVXL) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Fundamental valuation:AVXL Anavex Corp
Product sample of anavex.com

Investors utilize multiples to verify an asset's market value relative to its fundamental indicators. The forward P/E metric for the company compares the current share price with projected earnings for the coming year. This chart enables the rapid identification of valuation deviations from safe limits. For Anavex Life Sciences (AVXL), this indicator is critical, as future revenues depend on the approval of drugs for Alzheimer's and Parkinson's diseases. Low values may mask high clinical trial risks.

Competing companies

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|Supernus Corp - Future Price to Earnings Multiple|Projected Price to Earnings CPRX|Denali Therapeutics Inc. (DNLI) - Market Cap to Projected Earnings|Projected Price to Earnings HRMY (Harmony Corp)|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|Future Price to Earnings Multiple TRVI|PRAX - Future Price to Earnings|Future Price to Earnings Multiple CBLL (CeriBell, Inc.)|PRTA: Forward P/E Multiple|Price to Future Earnings Ratio ALEC|ANNX (Annexon Biosciences Inc.) - Forward P/E Multiple|omeros.com - Price to Expected Earnings Ratio|Future Price to Earnings Neurogene (NGNE)|Market Cap to Projected Earnings AC Immune SA|Forward P/E Multiple VYGR (voyagertherapeutics.com)|Forward P/E Multiple Neumora NMRA|Scilex Holding - Forward P/E Multiple|Projected Price to Earnings Ratio Tevogen Bio Inc.|Alpha Cognition (ACOG) - Future Price to Earnings|cogrx.com (CGTX) - Forward P/E Multiple|Future Price to Earnings Inhibikase Therapeutics|Cassava (SAVA) - Market Cap to Projected Earnings|Future Price to Earnings Assertio Therapeutics (ASRT)|Market Cap to Projected Earnings Coya|Vistagen - Projected Price to Earnings|Future Price to Earnings Multiple OVID|Acumen Pharmaceuticals Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio CervoMed Inc|ATHE: Forward P/E Multiple|Projected Price to Earnings Clene Nanomedicine|Future Price to Earnings PepGen Corp|Jupiter Neurosciences (JUNS) - Market Cap to Projected Earnings|Future Price to Earnings Relmada Therapeutics, Inc. (RLMD)|ANVS - Projected Price to Earnings Ratio|gracetx.com - Projected Price to Earnings|AIFF: Price to Future Earnings Ratio|Klotho Neurosciences - Forward P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MTVA (MetaVia Inc.) - Future Price to Earnings|Future Price to Earnings NeurAxis, Inc|Future Price to Earnings HSDT|Forward P/E Multiple PASG|Market Cap to Projected Earnings Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)